BRL 36650 is a new type of penicillin in which a formamido group has been introduced into the 6aL-position of the nucleus. The compound is highly active against aerobic gram-negative bacteria and is stable to a wide range of ,-lactamases produced by these organisms. 
In recent years there has been considerable interest in modifying the penicillin or cephalosporin nucleus at the 6a-(7a-)position. The introduction of a methoxy group was shown to increase the stability of the compound to bacterial ,-lactamases but usually at the expense of antibacterial activity (1) . To date a small number of methoxy-substituted P-lactams have achieved a balance between activity and ,Blactamase stability and found clinical utility. These include cefoxitin (6) , cefmetazole (2) , and moxalactam (7) with a cephalosporin or oxacephem nucleus but only temocillin in the penicillin series (5) . As part of a research program at Beecham, a large number of substituents have been introduced into the 6a-position of the penicillin nucleus. One of them, a formamido group, was found to confer the stability to bacterial r-lactamases associated with the methoxy substituent without compromising the antibacterial activity.
This report describes the properties in vitro of a semisynthetic penicillin derivative which contains the novel 6a-formamido substituent. The compound BRL 36650, sodium 6P-{D-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonylamino}-2- (3,4 - dihydroxyphenyl)acetamido}-6a-formamido-penicillinate ( Fig. 1) , is highly active against aerobic gram-negative bacteria, including Pseudomonas aeruginosa, and stable to the ,B-lactamases produced by these organisms. (ii) Hydrolysis studies. The stability of the compounds to the 1-lactamase preparations was assessed by the paper-tape bioassay procedure as described previously (5) . Cephaloridine was assayed against Sarcina lutea NCTC 8340, and the other compounds were assayed against Escherichia coli ESS. The rates of hydrolysis of BRL 36650 and the comparison compounds were determined relative to that of cephaloridine, which was arbitrarily assigned a value of 100. RESULTS Antibacterial activity. Table 1 shows the spectrum of antibacterial activity of BRL 36650 against a number of strains of gram-negative and gram-positive bacteria in DST agar. The compound was highly active against all members of the family Enterobacteriaceae, with most strains being inhibited at concentrations of 0.06 to 0.5 ,ug/ml. BRL 36650 also exhibited a high level of activity against other gramnegative bacilli, such as P. aeruginosa (including ticarcillinresistant strains), Acinetobacter calcoaceticus, Flavobacterium meningosepticum, H. influenzae, and Neisseria gonorrhoeae. The compound was relatively inactive (MIC = 32 ,ug/ml) against Bacteroides fragilis. BRL 36650 showed a moderate level of activity against Streptococcus pyogenes group A, was less active against group b streptococci, and was inactive against enterococci. Staphylococcus aureus, Listeria monocytogenes, and Clostridium difficile were resistant to BRL 36650 (MIC = >128 jig/ml).
The activity of BRL 36650 against a larger number of clinical isolates of the family Enterobacteriaceae is shown in Table 2 in comparison with other 3-lactams. It can be seen that against strains of E. coli and Klebsiella pneumoniae, most of which were resistant to ampicillin and cefazolin, BRL 36650 was more active than piperacillin or cefoperazone and similar in activity to cefotaxime, ceftazidime, moxalactam, and aztreonam. Against Klebsiella oxytoca, BRL 36650 was the most active compound, being slightly more active than moxalactam, cefotaxime, and ceftazidime. Piperacillin, cefoperazone, and aztreonam showed only poor activity against K. oxytoca. The Enterobacter strains tested were divided into two groups based on their susceptibility to cefotaxime. The first group contained strains that were inhibited by cefotaxime at a concentration of 8.0 jig/ml or less, whereas the second group comprised the more resistant strains which required at least 32 pLg of cefotaxime per ml for inhibition. Against the former group the MIC90 for all the test compounds, other than piperacillin, were of the order of 0.5 to 4.0 p.g/ml (Table 2 ). In contrast, the group showing decreased susceptibility to cefotaxime was also much less susceptible to the other standard compounds tested, whereas BRL 36650 inhibited 90% of the strains at a concentration the non-p-lactamase-producing strains but the least active aeruginosa tested were divided into two groups, depending against those producing the R-TEM enzyme. on their susceptibility to ceftazidime. It can be seen that Factors affecting activity. (i) Inoculum size. The artivity of against the majority of strains (ceftazidime MIC = <8.0 BRL 36650 was little affected by inoculum size. Increasing ,ug/ml), BRL 36650 was the most active antibiotic, with a the cell number from 104 to 106 CFU reduced the activity of MIC90 of 0.5 .g/ml compared with 4.0 jig/ml for ceftazidime the compound two-to fourfold ( Table 5 . In general, relatively resistant to the standard compounds but were the activity was little influenced by the composition of the edly decreased susceptibility to cefotaxime and moxalactam are becoming more common after treatment with these agents (4). The genera most often involved are Enterobacter and Pseudomonas. These bacteria characteristically produce an inducible 1-lactamase belonging to the Richmond and Sykes class 1 (3), although the more resistant strains have been shown to produce large quantities of this 1-lactamase constitutively (4) . The isolates tested in this study also proved to be considerably less susceptible to ceftazidime and to aztreonam but not to BRL 36650. Indeed, the penicillin inhibited 90% of resistant Enterobacter spp. isolates at 4.0 jig/ml compared with >64 jig/ml for cefotaxime and inhibited 90% of resistant P. aeruginosa isolates at 8.0 jig/ml compared with 64 ,ug/ml for ceftazidime.
The activity of BRL 36650 in vitro was reflected in the efficacy of the compound in vivo against experimental infections in mice, and in addition, BRL 36650 was found to be well tolerated in human volunteer studies (manuscripts in preparation). The results of all these studies are encouraging and justify clinical trials with BRL 36650.
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